腾讯网1 天
STTT：中国医学科学院肿瘤医院团队首次发现，GM-CSF或能逆转钙结合 ...
*仅供医学专业人士阅读参考最近这段时间，大家都被变幻莫测的初春天气折腾到够呛吧？至少奇点糕记忆里之前就没在3月初看到过大雪纷飞，超大的早晚温差也让穿衣服成了棘手难题。天气能忽冷忽热来回切换，但人体内的肿瘤免疫微环境就没这么容易改变了，像某些出名的免疫 ...
Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01
The FLAMINGO-01 DSMB met twice in 2024, most recently in December 2024, and recommended to continue the study as is without modification. No serious adverse events related to GLSI-100 have been ...
腾讯网3 天
中国医学科学院：肿瘤治疗新靶点A1，免疫疗效翻倍的秘密
点击蓝字关注我们【导读】免疫检查点阻断疗法（ICB）给癌症治疗带来了革命性的变化，但治疗反应却具有高度异质性，这凸显了开发预测性生物标志物和克服ICB耐药性的必要性。2025年3月17日，中国医学科学院肿瘤医院的研究团队在期刊《Signal ...
MyChesCo on MSN9 天
Savara Inc. Launches Convenient DBS Test for Diagnosing Rare Lung Disease
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has introduced the aPAP ClearPath Dried Blood Spot (DBS) Test in the United States ...
敏感肌美白的历史性突破，欧诗漫打破“敏暗”魔咒
《2023国人面部美白消费趋势白皮书》中的数据指出：80%以上的中国美白消费者认为自己是敏感肌，其中每5位女性中就有3位希望解决肌肤暗沉问题。当光电医美、猛药护肤与户外运动成为新常态，“敏暗红”三重奏正撕扯着现代女性的肌肤屏障。传统解决方案陷入两难： ...
Le Lézard13 天
Savara Announces U.S. Launch of the aPAP ClearPathtm Dried Blood Spot Test to Detect ...
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the launch of the aPAP ClearPath Dried Blood Spot (DBS) Test in the U.S., an ...
Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect ...
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...
Y-mAbs Therapeutics, Inc.: Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent ...
Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in January 2025 aimed to accelerate the clin ...
Y-mAbs announces publication of Phase 2 interim results on naxitamab
Y-mAbs Therapeutics (YMAB) announced the publication of interim data from a Phase 2 clinical trial evaluating naxitamab with granulocyte-macrophage colony-stimulating factor, GM-CSF, in patients with ...
GM Authority16 天
GM BEV3 Vehicle Platform
The GM BEV3 platform is a global architecture that’s also highly flexible. GM says that it is capable of supporting a wide variety of vehicles, particularly cars, crossovers, and commercial ...
Business.com16 天
6 Lessons in Corporate Ethics From the GM Recall
The 2014 General Motors recall is a tragic example of ethical misconduct. GM allegedly knew about faulty ignition switches linked to at least 124 deaths and 274 injuries for more than a decade. Yet it ...
Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and ...